Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    2011-07 GWAS
Previous Study | Return to List | Next Study

A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01598285
Recruitment Status : Terminated (Due to the low rate of recruitment.)
First Posted : May 15, 2012
Last Update Posted : January 14, 2019
Sponsor:
Collaborators:
Hoffmann-La Roche
Roche Farma, S.A
Information provided by (Responsible Party):
Spanish Breast Cancer Research Group

Brief Summary:

GEI-BEV-2011-01 is an Observational multicenter study. The study, involving 200 (100 non-responders and 100 best responders) metastatic breast cancer patients, will search for specific genetic variants (SNPs) and miRNA signatures associated with bevacizumab response. Only patients suffering from metastatic (disseminated at the time of diagnosis) breast cancer, treated with bevacizumab, will be included.

  1. -To identify genetic variants as bevacizumab response predictors in metastatic breast cancer
  2. To identify miRNA signatures in whole blood as bevacizumab response predictors in metastatic breast cancer patients.

The main endpoint will be progression-free survival (PFS)

The duration of the study will be approximately 18 months


Condition or disease
Breast Cancer Invasive Nos

Detailed Description:
In certain solid neoplasias, antiangiogenic therapies improve response rates and time to progression. However, treatment with antiangiogenic drugs do not improve patient´s overall survival, in addition to being quite toxic and expensive. It is therefore critical to identify reliable predictive factors for drug efficacy and potential toxicity. Pharmacogenomics and pharmacogenetics are emerging as important tools in the optimization of different therapeutic strategies against cancer. Thus, gene expression profiling and genome-wide association studies (GWAS) offer the promise to more effectively tailor individual cancer treatments by identifying new biomarkers for clinical efficacy. They likely represent a real progress in our understanding of cancer as a complex process and an improvement in patient management and treatment. This grant proposal is aimed at: i) identify genetic variants (SNPs) responsible for the different bevacizumab treatment response observed in metastatic breast cancer patients and ii) determine specific blood microRNA (miRNA) signatures associated with the bevacizumab response The reference endpoint for patient selection will be progression free survival (PFS). To increase the statistical significance of the study, patients will be categorized in two groups: non-responders (PFS<12 weeks) and best responders (PFS>52 weeks). Blood samples will be drawn prospectively from selected patients, they will be processed to obtain purified total DNA and RNA and, finally, they will be analyzed by next-gen GWAS and miRNA profiling, respectively. DNA samples will be hybridized to ultrahigh density Omni microarrays, containing 2.5 million genetic variants while RNA samples will be hybridized to Affymetrix microarrays containing an up-to-date collection of human miRNA sequences (miRBase v15, 1105 human miRNA probes). Standard computational analysis of both sets of microarray data will performed and the results will be correlated with the main endpoint of the study (PFS).

Layout table for study information
Study Type : Observational
Actual Enrollment : 26 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: A Combined Genome-Wide Association Study (GWAS) and microRNA (miRNA) Profiling Approach for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer
Actual Study Start Date : April 18, 2012
Actual Primary Completion Date : April 10, 2013
Actual Study Completion Date : April 10, 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer




Primary Outcome Measures :
  1. Genome-Wide Association Study (GWAS) and microRNA (miRNA) profiling for identification of genetic variants and blood miRNA signatures predictors of bevacizumab response. [ Time Frame: 18 months ]
    Genome-Wide Association Study (GWAS) and microRNA profiling will be performed from DNA and microRNA obtained from blood samples of metastatic breast cancer patients treated with Bevacizumab. Next-generation microarray thecnologies will be performed. Patients will be categorized in two groups: non-responders and best responders. Results of standard computational analysis of microarrays will be correlated with progression free survival data for identification of genetic variants and microRNA signatures predictors of Bevacizumab response


Biospecimen Retention:   Samples With DNA
Whole blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients suffering from metastatic (disseminated at the time of diagnosis) breast cancer, treated with bevacizumab.
Criteria

Inclusion Criteria:

  • patients with breast cancer, at a disseminated stage
  • patients treated with bevacizumab in combination with weekly paclitaxel as first line chemotherapy and who have progressed
  • alive patients authorizing the extraction and analysis of their biological samples.

Exclusion Criteria:

  • patients with a second neoplasia
  • deceased patients
  • patients who have not agreed to participate in the study
  • HER2 positive patients
  • patients with CNS metastases when first treated with bevacizumab in combination with paclitaxel
  • patients with local-regional recurrence only and
  • patients with status NED (resected metastases)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01598285


Locations
Layout table for location information
Spain
Hospital Clínico Universitario Virgen de la Victoria
Málaga, Spain, 29010
Sponsors and Collaborators
Spanish Breast Cancer Research Group
Hoffmann-La Roche
Roche Farma, S.A
Investigators
Layout table for investigator information
Study Director: Study Director Hospital Clínico Universitario Virgen de la Victoria
Additional Information:
Layout table for additonal information
Responsible Party: Spanish Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT01598285    
Other Study ID Numbers: GEICAM/2011-07
GEICAM/2011-07 ( Other Identifier: GEICAM/2011-07 )
First Posted: May 15, 2012    Key Record Dates
Last Update Posted: January 14, 2019
Last Verified: January 2019
Keywords provided by Spanish Breast Cancer Research Group:
Genome-Wide
GWAS
microRNA
miRNA
Bevacizumab Response Predictors
Metastatic Breast Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases